CERo Therapeutics (NASDAQ: CERO) has announced significant progress in its Phase 1 trial of CER-1236 for acute myeloid leukemia (AML). A patient in the first…
HOPE Therapeutics (NASDAQ: NRXP) has announced a significant expansion of its interventional psychiatry network through the acquisition of Cohen & Associates, a prominent practice based…
October 16, 2025
I-Mab Unveils Strategic Global Shift with Hong Kong IPO Plans and Rebrand to NovaBridge Biosciences
I-Mab (NASDAQ: IMAB), recognized as a global biotechnology platform company, has unveiled a strategic initiative to redefine its global standing. The endeavor involves a rebranding…
October 16, 2025
PRISM BioView Dive: Recent Report Projects Global Biotech Equipment Market to Accelerate Toward $144Bn by 2030 – Here’s Who to Watch
The biotechnology equipment sector is entering a new era of growth and innovation, driven by breakthroughs in cell and gene therapy, automation, and data-driven manufacturing….
October 16, 2025
AstraZeneca Commits $445 Million to Double Lokelma Production with Major Texas Expansion
AstraZeneca (NASDAQ: AZN) is deepening its investment in cardiorenal therapies with a $445 million expansion of its Coppell, Texas facility, the company’s sole global site…
October 16, 2025
SOPHiA GENETICS Introduces AI-Driven “Digital Twins” to Advance Data-Based Oncology Decision-Making
SOPHiA GENETICS (Nasdaq: SOPH) has unveiled a new research technology called SOPHiA DDM™ Digital Twins, designed to help oncologists simulate and evaluate cancer treatment strategies…
October 13, 2025
FDA Accepts MannKind’s Application to Expand Afrezza Inhaled Insulin Use to Children and Teens
If approved, Afrezza would become the first inhaled insulin option for patients as young as four years old. MannKind Corporation (NASDAQ: MNKD) announced that the…
September 08, 2025
LB Pharmaceuticals Targets $322 Million Valuation in Biotech IPO focusing on developing therapies for neuropsychiatric conditions Amid Industry Slowdown
LB Pharmaceuticals (NASDAQ: LBRX), a New York-based drug developer, announced plans on Monday to pursue a valuation of up to $321.6 million in its initial…
Regeneron Pharmaceuticals (NASDAQ: REGN) a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases is making headlines today, with…
July 24, 2025
FDA Accepts Atara Biotherapeutics’ BLA for Tab-cel®
Atara Biotherapeutics (NASDAQ: ATRA) has reached a pivotal milestone in its mission to transform treatment options for patients with life-threatening diseases. The U.S. Food and…
OKYO Pharma (Nasdaq: OKYO) announced encouraging top-line results from its Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain (NCP), a chronic and…
The woman’s health focused biopharmaceutical company Daré Bioscience (NASDAQ: DARE) has released encouraging interim results from its ongoing Phase 3 clinical trial evaluating Ovaprene®, a…